Enovis’s (NYSE:ENOV) Q3 2026 earnings results: revenue in line with expectations, stock soars
Enovis (NYSE:ENOV) reported Q3 2026 revenue of $558.7M, meeting estimates, and adjusted EPS of $0.88, beating estimates. The company reconfirmed its full-year revenue guidance of $2.34B and raised adjusted EPS guidance to $3.69. Operating margin improved to 0.6% from -102% YoY.
How this was made
The 30-second read
Why it matters
The earnings beat and guidance lift suggest a short-term rally, but margin concerns could temper enthusiasm.
Market read
Earnings surprise and guidance raise provide a clear trading catalyst for ENOV.
What to watch
Operating margin still low at 0.6%; cash flow remains modest.
Background
Enovis reported Q3 2026 results with revenue matching estimates and a notable EPS beat, subsequently raising its full-year EPS outlook.
Ticker impact
Q3 2026 earnings beat revenue and EPS estimates and raised full-year EPS guidance.
likely upward as market prices in stronger earnings and higher guidance
Revenue in line, EPS beat 14.8%, and EPS guidance lifted 1.7% indicate improved profitability.
Market effects
Positive for medical device/healthcare services sector as Enovis shows earnings resilience.
May lift other US-listed medtech stocks.
Limited to sector; no broad market effect.
Counterpoint
Guidance raise is modest; investors may question sustainability of margin improvement.
Key entities
- CompanyEnovis
US-listed medical device and healthcare services firm (NYSE:ENOV).
